Published 2026-09-02Market cap $2,328M8 sourced statements
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy · PHASE2,PHASE3 · n=390 · active not recruiting
What this sheet is scored on
call
Cash of $268M against operating outflow of $159M per quarter gives roughly 1.7 quarters of runway, clearing the readout 0.4 quarters out but leaving under a year. On these figures the company raises capital within four quarters.
151,043,781 shares outstanding against 172,318,894 if every outstanding option, warrant and convertible were exercised. In that case 12.4% of a gain in enterprise value would accrue to those holders rather than to current shareholders.
Registered design for NCT06309966: randomized, quadruple-masked, 390 participants (estimated). Primary outcome: Change from Baseline in 28-day average seizure frequency.
Designations disclosed: Fast Track, Orphan Drug, Priority Review Voucher. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.
This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.